Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression

Journal of Diabetes and its Complications

Volumn 23, Issue 2, 2009, Pages 124-129

  Zheng, Mao ^a   Ye, Shandong ^a   Zhai, Zhimin ^a   Chen, Yan ^a   Li, Xiucai ^a   Yang, Guangwei ^a   Fan, Aihong ^a   Wang, Yingxin ^b  

^a ANHUI PROVINCIAL HOSPITAL   (China)

^b Anhui Medical College   (China)

Author keywords

Diabetes mellitus; Diabetic mephropathy; Monocyte chemoattractant protein 1; Rosiglitazone

Indexed keywords

ALBUMIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RETINOID BINDING PROTEIN; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MECHANISM; KIDNEY; KIDNEY MASS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; UPREGULATION; URINARY EXCRETION;

ANIMALS; CHEMOKINE CCL2; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRINOLYTIC AGENTS; KIDNEY; MALE; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLIDINEDIONES;

EID: 60049086525     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2007.11.012     Document Type: Article

References (28)

1. Agarwal R. Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. American Journal of Physiology Renal Physiology 290 (2006) F600-F605
2. Bakris G., Viberti G., Weston W.M., Heise M., Porter L.E., and Freed M.I. Rosiglitazone reduces urinary albumin excretion in type II diabetes. Journal of Human Hypertension 17 (2003) 7-12
3. Banba N., Nakamura T., Matsumura M., Kuroda H., Hattori Y., and Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney International 58 (2000) 684-690
4. Bohle A., Bader R., Grund K.E., Mackensen S., and Neunhoeffer J. Serum creatinine concentration and renal interstitial volume. Analysis of correlations in endocapillary (acute) glomerulonephritis and in moderately severe mesangioproliferative glomerulonephritis. Virchows Archive A Pathological Anatomy and Histology 3751 (1977) 87-96
5. Buckingham R.E. Thiazolidinediones: Pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatology Research 33 (2005) 167-170
6. Chappey O., Dosquet C., Wautier M.P., and Wautier J.L. Advanced glycation end products, oxidant stress and vascular lesions. European Journal of Clinical Investigation 27 (1997) 97-108
7. Cooper M.E. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352 (1998) 213-219
8. Dalla Vestra M., Mussap M., Gallina P., Bruseghin M., Cernigoi A.M., Saller A., Plebani M., and Fioretto P.J. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. Journal of the American Society of Nephrology 16 Suppl 1 (2005) S78-S82
9. Egido J. Chemokines, chemokine receptors and renal disease. Kidney International 56 (1999) 347-348
10. Game B.A., He L., Jarido V., Nareika A., Jaffa A.A., Lopes-Virella M.F., and Huang Y. Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice. Atherosclerosis 192 (2007) 85-91
11. Gruden G., Setti G., Hayward A., Sugden D., Duggan S., Burt D., Buckingham R.E., Gnudi L., and Viberti G. Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: Inhibition by rosiglitazone. Journal of the American Society of Nephrology 16 (2005) 688-696
12. Han S.Y., Kim C.H., Kim H.S., Jee Y.H., Song H.K., Lee M.H., Han K.H., Kim H.K., Kang Y.S., Han J.Y., Kim Y.S., and Cha D.R. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Journal of the American Society of Nephrology 17 (2006) 1362-1372
13. Hisada Y., Sugaya T., Yamanouchi M., Uchida H., Fujimura H., Sakurai H., Fukamizu A., and Murakami K. Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. Journal of Clinical Investigation 103 (1999) 627-635
14. Isshiki K., Haneda M., Koya D., Maeda S., Sugimoto T., and Kikkawa R. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 49 (2000) 1022-1032
15. Kikuchi Y., Imakiire T., Yamada M., Saigusa T., Hyodo T., Hyodo N., Suzuki S., and Miura S. Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats. Nephrology Dialysis Transplantation 20 (2005) 1573-1581
16. Lee S., Kim W., Kang K.P., Moon S.O., Sung M.J., Kim D.H., Kim H.J., and Park S.K. Agonist of peroxisome proliferator-activated receptor-gamma, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model. Nephrology Dialysis Transplantation 20 (2005) 1057-1065
17. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. New England Journal of Medicine 338 (1998) 436-445
18. Morrissey J.J., and Klahr S. Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. American Journal of Physiology 274 (1998) F580-F586
19. Panchapakesan U., Pollock C.A., and Chen X.M. The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells. American Journal of Physiology Renal Physiology 287 (2004) F528-F534
20. Pistrosch F., Herbrig K., Kindel B., Passauer J., Fischer S., and Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54 (2005) 2206-2211
21. Ruiz-Ortega M., Bustos C., Hernández-Presa M.A., Lorenzo O., Plaza J.J., and Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. Journal of Immunology 161 (1998) 430-439
22. Sarafidis P.A., Lasaridis A.N., Nilsson P.M., Hitoglou-Makedou A.D., Pagkalos E.M., Yovos J.G., Pliakos C.I., and Tourkantonis A.A. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. American Journal of Hypertension 18 (2005) 227-234
23. Tanimoto M., Fan Q., Gohda T., Shike T., Makita Y., and Tomino Y. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metabolism 53 (2004) 1473-1479
24. Viedt C., Dechend R., Fei J., Hänsch G.M., Kreuzer J., and Orth S.R. MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor-kappaB and activating protein-1. Journal of the American Society of Nephrology 13 (2002) 1534-1547
25. Wada T., Furuichi K., Sakai N., Iwata Y., Yoshimoto K., Shimizu M., Takeda S.I., Takasawa K., Yoshimura M., Kida H., Kobayashi K.I., Mukaida N., Naito T., Matsushima K., and Yokoyama H. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney International 58 (2000) 1492-1499
26. Wolpe S.D., Davatelis G., Sherry B., Beutler B., Hesse D.G., Nguyen H.T., Moldawer L.L., Nathan C.F., Lowry S.F., and Cerami A. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. Journal of Experimental Medicine 167 (1988) 570-581
27. Yamashita H., Nagai Y., Takamura T., Nohara E., and Kobayashi K. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism 51 (2002) 403-408
28. Zafiriou S., Stanners S.R., Polhill T.S., Poronnik P., and Pollock C.A. Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses. Kidney International 65 (2004) 1647-1653